- Previous Close
3.4700 - Open
3.4282 - Bid 2.4300 x 200
- Ask 3.9000 x 200
- Day's Range
3.0300 - 3.4282 - 52 Week Range
2.4400 - 6.1600 - Volume
43,759 - Avg. Volume
35,250 - Market Cap (intraday)
27.393M - Beta (5Y Monthly) 1.49
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1500 - Earnings Date Nov 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.00
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
markertherapeutics.comRecent News: MRKR
View More
Performance Overview: MRKR
Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRKR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRKR
View MoreValuation Measures
Market Cap
27.39M
Enterprise Value
9.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.82
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-278.22%
Return on Assets (ttm)
-40.87%
Return on Equity (ttm)
-71.74%
Revenue (ttm)
3.73M
Net Income Avi to Common (ttm)
-10.31M
Diluted EPS (ttm)
-1.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
7.8M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.4M
Research Analysis: MRKR
View MoreCompany Insights: MRKR
MRKR does not have Company Insights